Sunny,

Vielen dank. Sehr nutzliche informationen !!

Dr. Drosten et-al paper is, once more a validation of Dr. Patterson work:

Quote:

---

The data shown in our manuscript support the well-known role of ACE2, which places the receptor and its co-factors as primary drug target. However, from a clinical perspective the main determinant for different clinical courses of COVID-19 infections is a hyperactivated, pathogenic immune response.

---

Quote:

---

Therefore, immune modulators should be considered as a primary therapeutic principle for treatment of COVID-19. The current focus in development of COVID-19 therapies is based on inhibition of immunological key players like IL6, TNF or interferon.
However, our data 5 suggest that targeting chemokine receptors could also offer a promising therapeutic option.

---

Quote:

---

Since binding of CCL2 or CCL3 to CCR1, CCR2 and CCR5 can induce monocyte recruitment into the lung parenchyma with consecutive recruitment and activation of further immune cells and epithelial damage, CCR1, CCR2, and CCR5 might represent promising anti-inflammatory targets in COVID-19.

---

Quote:

---

However, since we observed CCR2 expression neither in the upper nor in the lower respiratory tract of COVID-19 patients , CCR1 inhibition, possibly combined with CCR5 blockage, might be a potentially more promising strategy in SARS-CoV-2 infection.

---

Drs. Chua and Drosten (in Germany) are basically VALIDATING our Leronlimab !!!

So, we have validation from China (other paper) and German researchers on the MoA of eronlimab. The thing is, WE HAVE THE DRUG !!!.

We are missing FDA